Skip to main content

Table 1 Patient characteristics including treatment and pathological parameters

From: Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases

 

BoM/ nBM (N)

BM (N)

patients

40

40

deceased

14

14

Taxane (#)

30

38

 DTX

9

15

 Paclitaxel

17

14

 both

4

9

mean follow-up (##)

 days

2492.95

2545.15

 years

6.83

6.97

 age primary diagnosis (##) years

55.6

52.4

neoadjuvant therapy (#)

 yes

7

4

 no

29

29

 u

4

7

T (#)

 T1

9

7

 T2

15

13

 T3

5

7

 T4

6

7

 Tx

1

1

 Tis

0

1

 u

4

4

N (#)

 N0

10

16

 N1

13

11

 N2

5

4

 N3

8

5

 u

4

4

M (#)

 M0

17

23

 M1

15

8

 Mx

1

1

 u

7

8

grading (#) *

 G1

4

0

 G2

14

16

 G3

9

17

 u

13

7

ER (#) ***

 +

33

17

 -

5

19

 u

2

4

PR (#) *

 +

26

15

 -

12

20

 u

2

5

HER2/neu (#) *

 +

13

12

 -

24

21

 u

3

7

triple negative (#) *

 yes

3

9

 no

34

27

 u

3

4

intrinsic subtype (#) ***

 luminal

34

19

 basal-like

3

9

 Erb-B2 overexpression

0

8

 u

3

4

  1. BoM bone metastasis, nBM no brain metastasis, BM brain metastasis, u unknown. Statistical analysis was conducted using contingency analysis with likelihood-ratio/ Pearson test (#) or analysis of variance using one-way ANOVA (##). Significant differences are depicted as followed: * p<0.05; ** p<0.01; *** p<0.001